Latest Asx News

Octava Minerals Limited has had its trading suspension lifted following the announcement of a proposed capital raising, signaling renewed market activity for the mining explorer.

Octava Minerals secures $1.5 million in a placement to fund exploration and due diligence for acquiring the historically promising Federation copper-zinc-silver project in Western Tasmania.

Orpheus Uranium has secured a Native Title Mining Agreement with the Wilyakali people, unlocking advanced exploration at its Radium Hill South and Mundaerno projects. This milestone sets the stage for drilling approvals expected by late 2025.

Aurum Resources reports exceptional high-grade gold intercepts at its Boundiali Gold Project in Côte d'Ivoire, underpinning an aggressive 100,000m drilling campaign and a Pre-Feasibility Study due by year-end.

Peako Limited halted field exploration in the June quarter due to seasonal and logistical challenges, surrendered two tenements, and announced the resignation of its CEO, while maintaining a solid cash position.

Tesoro Gold has reported promising drilling results expanding its Ternera gold resource and secured A$11.1 million in fresh capital, positioning the El Zorro project for accelerated development.

Sierra Nevada Gold (ASX – SNX) has completed the purchase of the New Pass Gold Mine claims in Nevada, gaining 100% ownership and reporting promising gold grades in historic tailings. The company advances plans for bulk sampling and underground mining, while exploration at its Warrior project reveals new targets.

DeSoto Resources has ramped up exploration at its Northern Territory Spectrum Project, deploying a second drill rig and completing a significant deep hole at the Quantum Rare Earth Deposit.

Rapid Critical Metals has completed its acquisition of Silver Metal Group’s subsidiaries, marking a strategic expansion into silver, while appointing Byron Miles as its new Managing Director to steer the company’s next growth phase.

BlinkLab is advancing its FDA 510(k) clinical trials for autism and ADHD diagnostics, completing its U.S. autism pilot phase and expanding European ADHD recruitment. A recent $7.66 million capital raise supports these efforts as the company targets regulatory approvals in 2026.

Dimerix has secured a significant licensing agreement with Amicus Therapeutics for its kidney disease drug candidate DMX-200 in the US, receiving a US$30 million upfront payment and advancing its Phase 3 trial with FDA endorsement of a key clinical endpoint.

Stockland updates its interim dividend for the six months ending June 2025, confirming an estimated payout of AUD 0.172 per security and announcing the Dividend Reinvestment Plan price at AUD 5.43 with a 1% discount.